[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.159.197.114. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
June 1987

Adjunctive Imipramine in the Treatment of Postpsychotic DepressionA Controlled Trial

Author Affiliations

From the Departments of Psychiatry (Drs Siris and Rifkin and Ms Morgan) and Biostatistics (Dr Fagerstrom), Mount Sinai School of Medicine, City University of New York; and the Nathan Kline Research Institute, Orangeburg, NY, and New York State Psychiatric Institute, New York (Mr Cooper).

Arch Gen Psychiatry. 1987;44(6):533-539. doi:10.1001/archpsyc.1987.01800180043008
Abstract

• The efficacy of adjunctive imipramine hydrochloride treatment for syndromally defined postpsychotic depression was assessed in a six-week, double-blind, placebo-controlled study. All patients had been diagnosed as having schizophrenia or schizoaffective disorder, all were receiving stable doses of fluphenazine decanoate, and all had received benztropine mesylate in an attempt to rule out neuroleptic-induced akinesia. Patients randomized to imipramine therapy fared significantly better in terms of their global improvement and in terms of individual symptoms that are components of the depression syndrome. There were no significant differences in outcome psychosis ratings or side effects. This study indicates the existence of an identifiable syndrome of secondary depression in this patient group that is likely to respond favorably to treatment with adjunctive imipramine.

×